Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 20,850 shares at $21.58 ($473K) on 2025-07-17, disclosed to the SEC on 2025-07-21.
Scheduled sale ($473k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.58 | 4,150 | $90K | 18.9% |
| 2 | $22.69 | 4,687 | $106K | 22.5% |
| 3 | $22.69 | 4,687 | $106K | 22.5% |
| 4 | $23.37 | 3,663 | $86K | 18.1% |
| 5 | $23.37 | 3,663 | $86K | 18.1% |
| Total | $22.71 avg | 20,850 |
| $473K |
| 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |